NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

KAPA

Kairos Pharma Ltd

May 09 • 04:00PM ET

0.6811

Dollar change -0.0739
Percentage change -9.79	%

Healthcare • Biotechnology • USA • AMEX

Index	-	P/E	-	EPS (ttm)	-0.20	Insider Own	57.73%	Shs Outstand	13.74M	Perf Week	-16.25%
Market Cap	11.63M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	0.07%	Shs Float	7.22M	Perf Month	-31.89%
Income	-2.60M	PEG	-	EPS next Q	-0.05	Inst Own	0.21%	Short Float	0.34%	Perf Quarter	-50.64%
Sales	0.00M	P/S	-	EPS this Y	1.45%	Inst Trans	-91.77%	Short Ratio	0.20	Perf Half Y	-49.17%
Book/sh	0.35	P/B	1.96	EPS next Y	-69.12%	ROA	-72.50%	Short Interest	0.02M	Perf Year	-
Cash/sh	0.07	P/C	9.16	EPS next 5Y	-	ROE	-192.96%	52W Range	0.67 - 4.00	Perf YTD	-55.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.37%	ROI	-54.50%	52W High	-82.97%	Beta	-
Dividend TTM	-	Quick Ratio	4.20	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.18%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	4.20	EPS Y/Y TTM	-40.21%	Oper. Margin	-	RSI (14)	30.53	Volatility	12.34% 9.94%
Employees	4	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.33
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	18.05%	Payout	-	Rel Volume	0.73	Prev Close	0.75
Sales Surprise	-	EPS Surprise	16.67%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	125.27K	Price	0.68
SMA20	-20.85%	SMA50	-27.69%	SMA200	-50.12%	Trades		Volume	91,454	Change	-9.79%

May-06-25 08:00AM	Kairos Pharma, Ltd. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:00AM	Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire)
Apr-24-25 08:00AM	Kairos Pharma Ltd. Provides Letter to Stockholders (Business Wire)
Apr-17-25 08:00AM	Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer (Business Wire) +5.80%
Apr-04-25 09:40AM	Block upgraded, Nvidia downgraded: Wall Streets top analyst calls (TipRanks) +12.77%
07:00AM	Loading…
Mar-31-25 07:00AM	Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer (Business Wire)
Mar-28-25 09:03AM	CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105 (Newsfile) -5.01%
Mar-27-25 04:05PM	Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events (Business Wire)
Mar-20-25 07:30AM	Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer (Business Wire)
Feb-26-25 07:00AM	Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds Potential as Therapeutics for Melanoma and Glioblastoma (Business Wire) +8.77%
Feb-18-25 08:30AM	Kairos Pharma Announces New Department of Defense Funding for Research of ENV205 (Business Wire)
Feb-11-25 08:30AM	Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial (Business Wire)
Feb-06-25 08:30AM	Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compounds Potential as a Therapeutic for Melanoma and Glioblastoma (Business Wire) -8.86%
Jan-28-25 08:15AM	Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 (Business Wire)
Jan-21-25 08:30AM	Kairos Pharma Provides Business Update and Outlook into 2025 (Business Wire) -8.09%
08:15AM	Loading…
Jan-07-25 08:15AM	Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit (Business Wire)
Dec-16-24 12:15PM	Kairos Pharma to Participate in The Microcap Conference in January 2025 (ACCESSWIRE)
Dec-03-24 08:30AM	Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial (Business Wire)
Nov-19-24 08:30AM	Kairos Pharma Approved to Dual List on Upstream (GlobeNewswire) -14.04%
Oct-22-24 09:00AM	Kairos Pharma to Present at the LD Micro Main Event XVII (GlobeNewswire)
Oct-14-24 06:00AM	Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges (News Direct) +7.80%
Oct-09-24 04:30PM	Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-24-24 04:20PM	Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients (GlobeNewswire) -7.46%
Sep-17-24 04:29PM	Kairos Pharma Closing of $6.2 Million Initial Public Offering (GlobeNewswire) -5.38% -6.50%
Sep-16-24 10:49AM	Kairos Pharma Prices $6.2 Million Initial Public Offering (GlobeNewswire)

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murali Ramachandran	VP of Research and Development	Nov 25 '24	Buy	1.59	200	318	133,057	Nov 25 08:30 PM
Samuelson Doug	Chief Financial Officer	Nov 22 '24	Buy	1.50	2,500	3,750	60,796	Nov 25 06:03 AM
Yu John S	CEO and Chairman	Nov 20 '24	Buy	1.44	4,000	5,760	5,341,837	Nov 21 09:53 PM

Open in Screener

GNLX

Genelux Corp

May 09 • 04:00PM ET

2.96

Dollar change +0.11
Percentage change 3.86	%

Healthcare • Biotechnology • USA • NASD

Peers: LLY VRTX MRNA REGN PFE NVS GILD BMY AMGN BIIB

| Held by: VTI VXF IWC CNCR CHNA AVSC DFAC RFLR BTEC

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	13.23%	Shs Outstand	37.73M	Perf Week	12.55%
Market Cap	111.69M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-0.57%	Shs Float	32.74M	Perf Month	28.14%
Income	-29.51M	PEG	-	EPS next Q	-0.21	Inst Own	13.53%	Short Float	7.03%	Perf Quarter	-30.84%
Sales	0.00M	P/S	-	EPS this Y	6.58%	Inst Trans	-6.41%	Short Ratio	11.59	Perf Half Y	-3.27%
Book/sh	0.79	P/B	3.74	EPS next Y	-8.54%	ROA	-92.71%	Short Interest	2.30M	Perf Year	-18.90%
Cash/sh	0.93	P/C	3.18	EPS next 5Y	14.92%	ROE	-131.36%	52W Range	1.60 - 5.89	Perf YTD	25.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-14.03%	ROI	-94.30%	52W High	-49.70%	Beta	-0.36
Dividend TTM	-	Quick Ratio	4.67	Sales past 5Y	-38.75%	Gross Margin	-	52W Low	85.00%	ATR (14)	0.32
Dividend Ex-Date	-	Current Ratio	4.67	EPS Y/Y TTM	9.16%	Oper. Margin	-	RSI (14)	54.28	Volatility	13.91% 11.15%
Employees	24	Debt/Eq	0.06	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	17.60
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	26.64%	Payout	-	Rel Volume	0.54	Prev Close	2.85
Sales Surprise	-	EPS Surprise	13.40%	Sales Q/Q	-100.00%	Earnings	May 06 AMC	Avg Volume	198.51K	Price	2.96
SMA20	10.33%	SMA50	-3.01%	SMA200	3.30%	Trades		Volume	106,656	Change	3.86%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-24	Initiated	Guggenheim	Buy	$8
Aug-28-24	Initiated	ROTH MKM	Buy	$10
Nov-27-23	Initiated	H.C. Wainwright	Buy	$35
Sep-12-23	Initiated	Maxim Group	Buy	$40
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy	$10

May-06-25 04:10PM	Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -7.17%
May-01-25 04:05PM	Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire) -9.85% +8.45%
Apr-18-25 09:40AM	Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 04:10PM	Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -12.34%
09:35AM	Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
08:31AM	Loading…
Mar-25-25 08:31AM	Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.60%
08:30AM	Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease (GlobeNewswire)
08:30AM	Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer (GlobeNewswire)
Mar-02-25 09:39AM	Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-03-25 06:45AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) -10.63%
Dec-13-24 07:01AM	Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright (GlobeNewswire) -7.54%
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -19.73%
Nov-14-24 04:05PM	Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Nov-06-24 04:01PM	Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-25-24 01:01PM	Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp (GuruFocus.com)
11:27AM	Loading…
Oct-23-24 11:27AM	Genelux doses first subject in Phase II trial of NSCLC treatment (Clinical Trials Arena)
Oct-22-24 04:01PM	Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-09-24 04:15PM	Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.94%
Aug-14-24 09:54PM	GNLX Stock Earnings: Genelux Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-12-24 05:16PM	Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds (Insider Monkey) -6.57%
Jul-30-24 07:00AM	Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 (GlobeNewswire)
May-24-24 08:00AM	Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -43.04%
May-23-24 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire) -5.35%
May-09-24 11:53PM	GNLX Stock Earnings: Genelux Misses EPS for Q1 2024 (InvestorPlace) +6.07%
04:25PM	Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Apr-26-24 09:35AM	Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-23-24 09:35AM	Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-05-24 09:35AM	After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) (Zacks)
12:00PM	Loading…
Apr-04-24 12:00PM	All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy (Zacks)
Apr-02-24 07:52AM	GNLX Stock Earnings: Genelux Misses EPS for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -18.51%
Dec-15-23 03:01PM	Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX) (GuruFocus.com) -13.23%
Nov-27-23 07:00AM	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer (GlobeNewswire)
Nov-14-23 05:50PM	Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire) -7.61%
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-19-23 03:01PM	Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX) (GuruFocus.com) +8.04%
Sep-15-23 03:03PM	Director John Smither Sells 900 Shares of Genelux Corp (GNLX) (GuruFocus.com)
Sep-14-23 01:21PM	10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX) (GuruFocus.com)
07:00AM	Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.69%
Aug-28-23 07:00AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) +11.01%
Aug-14-23 07:00AM	Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-02-23 04:00PM	Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023 (GlobeNewswire) +5.52%
01:08AM	10 Recent IPOs in 2023 to Consider (Insider Monkey)
Jul-28-23 10:54AM	Why Shares of Genelux Climbed This Week (Motley Fool) -9.38%
Jul-20-23 04:45PM	Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires (GlobeNewswire) -10.85% -15.77%
Jul-10-23 07:00AM	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology (GlobeNewswire)
Jun-29-23 07:00AM	Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire)
Jun-22-23 07:00AM	Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 (GlobeNewswire) -7.05%
Jun-12-23 07:00AM	Genelux Corporation Announces $18 Million Private Placement (GlobeNewswire) +7.58%
Jun-01-23 05:19PM	Why Shares of Genelux Corporation Jumped This Week (Motley Fool) +6.62%
May-25-23 04:01PM	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology (GlobeNewswire) +6.62%
May-15-23 07:00AM	Genelux Corporation Announces $33 Million Private Placement (GlobeNewswire) -9.06%
Mar-23-23 07:00AM	Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 (GlobeNewswire)
Jan-25-23 09:00PM	Genelux Corporation Announces Pricing of Initial Public Offering (GlobeNewswire)

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tyree James L	Director	Dec 30 '24	Sale	2.46	3,460	8,512	45,791	Dec 30 07:48 PM
JAMES L TYREE	Director	Dec 30 '24	Proposed Sale	2.46	3,460	8,512		Dec 30 04:10 PM
Zindrick Thomas	President and CEO	Dec 16 '24	Sale	2.34	14,315	33,497	37,372	Dec 18 04:35 PM
Zak Lourie S.	Chief Financial Officer	Dec 16 '24	Sale	2.34	2,103	4,921	40,802	Dec 18 04:35 PM
Smalling Ralph	Head of Regulatory	Dec 16 '24	Sale	2.34	2,510	5,873	16,322	Dec 18 04:35 PM
Cappello Joseph	VP, Pharmaceutical Development	Dec 16 '24	Sale	2.34	6,300	14,742	14,653	Dec 18 04:35 PM
Szalay Aladar	10% Owner	Sep 12 '24	Sale	2.73	31,777	86,732	632,901	Sep 13 06:22 PM
Szalay Aladar	10% Owner	Sep 13 '24	Sale	2.57	33,080	84,946	599,821	Sep 13 06:22 PM
Tyree James L	Director	Sep 11 '24	Sale	2.60	1,730	4,499	47,521	Sep 12 08:40 PM
Szalay Aladar	10% Owner	Sep 11 '24	Sale	2.62	31,376	82,227	664,678	Sep 11 06:23 PM
Szalay Aladar	10% Owner	Sep 09 '24	Sale	2.70	23,383	63,200	716,438	Sep 11 06:23 PM
Szalay Aladar	10% Owner	Sep 10 '24	Sale	2.51	20,384	51,182	696,054	Sep 11 06:23 PM
JAMES L TYREE	Director	Sep 11 '24	Proposed Sale	2.51	1,730	4,342		Sep 11 04:20 PM
SZALAY 2010 RETAINED ANNUITY T	10% Owner	Sep 09 '24	Proposed Sale	2.80	140,000	392,000		Sep 06 07:00 PM
Szalay Aladar	10% Owner	Sep 03 '24	Sale	2.09	42,818	89,614	739,821	Sep 06 05:08 PM
Szalay Aladar	10% Owner	Aug 30 '24	Sale	2.17	142,589	309,846	782,639	Aug 30 07:58 PM
Szalay Aladar	10% Owner	Aug 29 '24	Sale	1.98	107,045	211,960	925,228	Aug 30 07:58 PM
Szalay Aladar	10% Owner	Aug 28 '24	Sale	2.05	15,918	32,605	1,032,273	Aug 30 07:58 PM
Szalay Aladar	10% Owner	Aug 27 '24	Sale	2.11	51,630	108,862	1,048,191	Aug 27 07:23 PM
Szalay Aladar	10% Owner	Aug 23 '24	Sale	2.29	40,000	91,416	1,099,821	Aug 27 07:23 PM
SZALAY 2010 RETAINED ANNUITY T	10% Owner	Aug 23 '24	Proposed Sale	2.18	400,000	872,000		Aug 22 05:08 PM
Yu Yong	VP, Clinical Trial Operations	Jun 24 '24	Sale	2.12	6,849	14,520	10,869	Jul 08 04:30 PM
Ryder Sean	General Counsel	Jun 24 '24	Sale	2.12	5,496	11,652	19,388	Jul 08 04:30 PM
Jewett Caroline	Head of Quality	Jun 24 '24	Sale	2.12	4,961	10,517	16,174	Jul 08 04:30 PM
Szalay Aladar	10% Owner	May 15 '24	Sale	3.66	17,094	62,624	1,139,821	May 15 05:59 PM
Szalay Aladar	10% Owner	May 14 '24	Sale	3.58	15,426	55,274	1,156,915	May 15 05:59 PM
Szalay Aladar	10% Owner	May 13 '24	Sale	3.62	3,446	12,478	1,172,341	May 15 05:59 PM

KAPA

Kairos Pharma Ltd

GNLX

Genelux Corp

Upgrade your FINVIZ experience